KYTXKyverna Therapeutics, Inc.

1. Sep 24, 2026Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis.Regulation FD disclosure · press release
2. Aug 11, 2026Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results.Earnings release · press release
3. Jul 27, 2026As previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc. (“ElevateBio”), pursuant to which ElevateBio has …Material agreement entered · Form 8-K
4. Jul 9, 2026As previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into that certain Loan and Security Agreement (the “Loan and Security Agreement”) with Oxford Finance LLC, as collateral agent (the “Collateral Agent”), and certain lenders from time to time party thereto (the “Lenders”)Material agreement entered · Form 8-K
5. May 18, 2026Appointment of Gregory Martini as Chief Financial Officer On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”)Director or officer change · Form 8-K
6. May 12, 2026Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results.Earnings release · press release
7. May 4, 2026On May 4, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Nadia Dac as the Company’s Chief Commercial Officer, effective May 4, 2026.Other event · Form 8-K
8. Apr 22, 2026AAN April 22, 2026 ©2026 Kyverna Therapeutics, Inc.Regulation FD disclosure · press release
9. Apr 22, 2026Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting.Regulation FD disclosure · press release
10. Apr 20, 2026Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks.Regulation FD disclosure · press release
11. Mar 26, 2026Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.